摘要
用抗人T淋巴细胞单兔隆抗体SMU3(抗CD3),SMU8(抗CD8)治疗32例再生障碍性贫血,基本治愈6例,缓解7例,明显进步11例,无效8例,有效率75%(24/32)。治疗前T淋巴细胞业群CD4/CD8比例倒置,淋巴细胞表面HLA-DR抗原表达增高;治疗后CD4/CD8比例恢复正常,HLA-DR表达降低。无血清病及血细胞减少等严重毒副作用。
The monoclonal anti human T lymphocyte antibodies SMU3 (anti CD3) and SMU8 (anti CD8) were used to treat 32 patients with aplastic anemia. The results showed that 6 patients were cured, remission and good response were achieved in 7 and 11 respectively. The other 8 patients had no response. The effective rate was 75% (24/32). The T cell subsets CD4/CD8 ratio was inverse and expression HLA DR antigen on the lymphocytes surface was higher before SMU3 and SMU8 therapy, and they returned to normal after therapy. No severe toxic and side effect such as serum disease or hematocytopenia was found.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
1996年第3期171-173,共3页
Medical Journal of Chinese People's Liberation Army